Taipei Medical University

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Liu Y
------>authors3_c=
------>paper_class1=1
------>Impact_Factor=3.398
------>paper_class3=2
------>paper_class2=1
------>vol=271
------>confirm_bywho=leehorng
------>insert_bywho=ycliang
------>Jurnal_Rank=37.1
------>authors4_c=
------>comm_author=
------>patent_EDate=None
------>authors5_c=
------>publish_day=1
------>paper_class2Letter=None
------>page2=305
------>medlineContent=
------>unit=E0310
------>insert_date=20080801
------>iam=7
------>update_date=None
------>author=???
------>change_event=4
------>ISSN=
------>authors_c=
------>score=500
------>journal_name=Cancer Lett.
------>paper_name=Anti-angiogenic action of 5,5-diphenyl-2-thiohydantoin-N10 (DPTH-N10).
------>confirm_date=20081215
------>tch_id=089135
------>pmid=18649995
------>page1=294
------>fullAbstract=Previously, we demonstrated that 5,5-diphenyl-2-thiohydantoin (DPTH) exerts an anti-proliferation effect on subcultured human umbilical vein endothelial cells (HUVEC). In the present study, we show that 2(naphthalen-2-ylmethylsulfanyl)-5,5-diphenyl-1,5-dihydro-imidazol-4-one (DPTH-N10), a derivative compound of DPTH, exerts a 5 times stronger inhibition of [3H]thymidine incorporation into HUVEC as compared with DPTH and at very low concentrations (0-20 microM) inhibited DNA synthesis and decreased cell number in cultured HUVEC in a concentration- and time-dependent manner, but not in human fibroblasts. [3H]thymidine incorporation analysis demonstrated that treatment of HUVEC with DPTH-N10 arrested the cell at the G0/G1 phase of the cell cycle. Western blot analysis revealed that the protein level of p21 in HUVEC increased after DPTH-N10 treatment. In contrast, the protein levels of p27, p53, cyclins A, D1, D3 and E, cyclin-dependent kinase (CDK)2, and CDK4 in HUVEC were not changed significantly after DPTH-N10 treatment. Immunoprecipitation showed that the formation of the CDK2-p21 complex, but not the CDK2-p27, CDK4-p21, and CDK4-p27 complex, was increased in the DPTH-N10-treated HUVEC. Kinase assay further demonstrated that CDK2, but not CDK4, kinase activity was decreased in the DPTH-N10-treated HUVEC. Pretreatment of HUVEC with a p21, but not p27, antisense oligonucleotide reversed the DPTH-N10-induced inhibition of [3H]thymidine incorporation into HUVEC. Taken together, these data suggest that DPTH-N10 inhibits HUVEC proliferation by increasing the level of p21 protein, which in turn inhibits CDK2 kinase activity, and finally interrupts the cell cycle. Capillary-like tube formation, aortic ring culture, and chick embryo chorioallantoic membrane (CAM) assays further demonstrated the anti-angiogenic effect of DPTH-N10.
------>tmu_sno=None
------>sno=18755
------>authors2=Wu J
------>authors3=Ho PY
------>authors4=Chen LC
------>authors5=Chen CT
------>authors6=Liang YC, Cheng CK, Lee WS.
------>authors6_c=
------>authors=Liu Y
------>delete_flag=0
------>SCI_JNo=None
------>authors2_c=
------>publish_area=0
------>updateTitle=Anti-angiogenic action of 5,5-diphenyl-2-thiohydantoin-N10 (DPTH-N10).
------>language=1
------>check_flag=None
------>submit_date=None
------>country=None
------>no=
------>patent_SDate=None
------>update_bywho=None
------>publish_year=2008
------>submit_flag=None
------>publish_month=1
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z